Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Xaluritamig in localized intermediate or high-risk prostate cancer
NCT06613100Phase 1Recruiting
- Sponsor
- Amgen
- Start
- Nov 2024
- Primary completion
- Feb 2027
- Modality
- Bispecific Antibodies, T-cell Engagers
- Countries
- 2
01
Overview
Phase 1, open-label trial of xaluritamig in prostate cancer (PCa) (2 cohorts), sponsored by Amgen. Primary endpoints: Treatment-emergent Adverse Events up to 45 months, Treatment-related Adverse Events up to 28 months and 2 more. Started Nov 2024; status: recruiting.
02
Drugs
xaluritamig
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT06613100.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06613100.